Allakos Inc. (ALLK)
NASDAQ: ALLK · Real-Time Price · USD
1.200
-0.090 (-6.98%)
Dec 20, 2024, 4:00 PM EST - Market closed
Allakos Employees
Allakos had 131 employees as of December 31, 2023. The number of employees increased by 8 or 6.50% compared to the previous year.
Employees
131
Change (1Y)
8
Growth (1Y)
6.50%
Revenue / Employee
n/a
Profits / Employee
-$1,364,466
Market Cap
107.21M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Inotiv | 2,055 |
MDxHealth | 300 |
Editas Medicine | 265 |
Leap Therapeutics | 54 |
Acumen Pharmaceuticals | 52 |
Eupraxia Pharmaceuticals | 29 |
Protara Therapeutics | 27 |
MediciNova | 13 |
ALLK News
- 2 days ago - Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - PRNewsWire
- 6 weeks ago - Allakos Runs Up Into A Near-Term Catalyst - Seeking Alpha
- 6 weeks ago - Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers - GlobeNewsWire
- 4 months ago - Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results - GlobeNewsWire
- 6 months ago - The Schall Law Firm Begins Probe Into Claims Against Allakos Inc And Urges Affected Investors To Participate - Accesswire
- 6 months ago - The Schall Law Firm Initiates Investigation Into Allegations Against Allakos Inc And Encourages Impacted Investors To Engage - Accesswire
- 6 months ago - Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile - GlobeNewsWire